CY1119603T1 - Οιστρογονικα παραγωγα για χρηση στην αγωγη νευρολογικων διαταραχων - Google Patents

Οιστρογονικα παραγωγα για χρηση στην αγωγη νευρολογικων διαταραχων

Info

Publication number
CY1119603T1
CY1119603T1 CY20171101193T CY171101193T CY1119603T1 CY 1119603 T1 CY1119603 T1 CY 1119603T1 CY 20171101193 T CY20171101193 T CY 20171101193T CY 171101193 T CY171101193 T CY 171101193T CY 1119603 T1 CY1119603 T1 CY 1119603T1
Authority
CY
Cyprus
Prior art keywords
neurological disorders
treatment
estrogenic derivatives
estrogenic
derivatives
Prior art date
Application number
CY20171101193T
Other languages
English (en)
Inventor
Jean-Michel Foidart
Ekaterine Tskitishvili
Original Assignee
Université de Liège
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université de Liège filed Critical Université de Liège
Publication of CY1119603T1 publication Critical patent/CY1119603T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Η εφεύρεση αφορά προφυλακτικές και θεραπευτικές εφαρμογές συγκεκριμένων οιστρογονικών συστατικών όπως estetrol σε νευρολογικές διαταραχές όπως υποξική-ισχαιμική εγκεφαλοπάθεια των νεογνών (ΥΙΕ).
CY20171101193T 2012-04-19 2017-11-14 Οιστρογονικα παραγωγα για χρηση στην αγωγη νευρολογικων διαταραχων CY1119603T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12164741.6A EP2653163A1 (en) 2012-04-19 2012-04-19 Estrogenic components for use in the treatment of neurological disorders
EP13714917.5A EP2838539B1 (en) 2012-04-19 2013-04-08 Estrogenic derivatives for use in the treatment of neurological disorders.
PCT/EP2013/057279 WO2013156329A1 (en) 2012-04-19 2013-04-08 Estrogenic components for use in the treatment of neurological disorders.

Publications (1)

Publication Number Publication Date
CY1119603T1 true CY1119603T1 (el) 2018-04-04

Family

ID=48050711

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101193T CY1119603T1 (el) 2012-04-19 2017-11-14 Οιστρογονικα παραγωγα για χρηση στην αγωγη νευρολογικων διαταραχων

Country Status (19)

Country Link
US (1) US9238035B2 (el)
EP (2) EP2653163A1 (el)
JP (1) JP6139662B2 (el)
CN (1) CN104379148B (el)
AU (1) AU2013248481B2 (el)
CA (1) CA2869902C (el)
CY (1) CY1119603T1 (el)
DK (1) DK2838539T3 (el)
ES (1) ES2647111T3 (el)
HR (1) HRP20171627T1 (el)
HU (1) HUE034902T2 (el)
LT (1) LT2838539T (el)
NO (1) NO2838539T3 (el)
PL (1) PL2838539T3 (el)
PT (1) PT2838539T (el)
RS (1) RS56595B1 (el)
RU (1) RU2627846C2 (el)
SI (1) SI2838539T1 (el)
WO (1) WO2013156329A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
WO2012164095A1 (en) 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US11638745B2 (en) * 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
UA123098C2 (uk) * 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
SI3310346T1 (sl) * 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10894014B2 (en) * 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
PE20231714A1 (es) 2015-06-18 2023-10-23 Estetra Sprl Unidad de dosificacion orodispersable que contiene un componente estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN107260712A (zh) * 2017-06-22 2017-10-20 中国人民解放军第三军医大学 奥培米芬在制备促进髓鞘形成和再生的药物中的应用
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
CN113243332B (zh) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） 一种广泛脑区神经元树突发育障碍动物模型的制备与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
AU2003274943A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Use of estetrol and analogues for treating or preventing cardiovascular pathologies, in particular atherosclerosis
ES2274252T3 (es) * 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
EP2698167A3 (en) * 2005-09-26 2014-03-05 The Regents of The University of California Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
WO2007081206A1 (en) * 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
US8367647B2 (en) * 2007-06-21 2013-02-05 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
AU2008325211B2 (en) * 2007-11-06 2014-11-13 Signal Coordinating Therapy, Inc. Compositions and methods for treating Parkinson's disease and related disorders
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用

Also Published As

Publication number Publication date
RS56595B1 (sr) 2018-02-28
AU2013248481B2 (en) 2017-02-16
SI2838539T1 (sl) 2017-12-29
NO2838539T3 (el) 2018-01-13
CN104379148B (zh) 2017-08-25
WO2013156329A1 (en) 2013-10-24
EP2838539B1 (en) 2017-08-16
US9238035B2 (en) 2016-01-19
DK2838539T3 (da) 2017-11-27
PL2838539T3 (pl) 2018-01-31
JP2015514731A (ja) 2015-05-21
LT2838539T (lt) 2017-11-27
HUE034902T2 (hu) 2018-03-28
ES2647111T3 (es) 2017-12-19
PT2838539T (pt) 2017-11-15
HRP20171627T1 (hr) 2017-12-01
JP6139662B2 (ja) 2017-05-31
RU2014145800A (ru) 2016-06-10
RU2627846C2 (ru) 2017-08-14
CN104379148A (zh) 2015-02-25
AU2013248481A1 (en) 2014-10-30
EP2838539A1 (en) 2015-02-25
CA2869902A1 (en) 2013-10-24
CA2869902C (en) 2019-07-02
EP2653163A1 (en) 2013-10-23
US20150133419A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
CY1119603T1 (el) Οιστρογονικα παραγωγα για χρηση στην αγωγη νευρολογικων διαταραχων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500525A1 (en) Formulations of enzalutamide
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
EA201391106A1 (ru) Новые гетероциклические производные
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
TR201819263T4 (tr) Nörolojik hastalıkların tedavisi için pantotenat türevleri.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
CY1118118T1 (el) Συνεργατικες θεραπειες cannabidiol μαζι με υποθερμια για νευρο-προστασια
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
CY1114438T1 (el) Δοσολογικο σχημα ρινικου σπρευ ολοπαταδινης για παιδια